Wheeler Bio, a contract development and manufacturing organization, or CDMO, for next-generation protein therapeutics, will begin production for customers next month in the 35,000-square-foot Ziggurat building in downtown Oklahoma City.
CEO Jesse McCool launched the company close to three years ago with the intention of filling a gap that exists between drug discovery and scale-up manufacturing of small-molecule biologic drugs used for cancer and autoimmune conditions. McCool reflected Thursday on the company milestone.